Clinical Report: The Sm29 Antigen Modulates Transcriptomic and Regulatory Profiles in Different Clinical Forms of Leprosy
Overview
This study evaluates the immunomodulatory effects of the Sm29 antigen on leprosy, highlighting its regulation of immune responses in different clinical forms, particularly reversal reaction (RR) and erythema nodosum leprosum (ENL).
Background
Leprosy, caused by Mycobacterium leprae, presents significant clinical challenges due to inflammatory reactions that can lead to increased morbidity. Understanding the immune response in leprosy is crucial for developing effective treatments.
Data Highlights
The study utilized peripheral blood mononuclear cells (PBMCs) stimulated with sonicated M. leprae and rSm29 antigen, followed by RNA sequencing and differential expression analysis.
Key Findings
The Sm29 antigen modulates immune response pathways in leprosy, particularly in reactional forms. In RR, Sm29 increased IL10 levels and modulated CSF2, while in ENL, it affected IL1B and FN1 gene expressions. Top differentially expressed genes in RR included C2CD4B, CEMIP, and IL23A, while these were less expressed in ENL. Sm29 exhibited an opposite effect in RR compared to ENL.
Clinical Implications
The findings indicate that the Sm29 antigen may modulate immune responses in leprosy during reactional episodes.
Conclusion
The study highlights the modulation of immune responses in leprosy by the Sm29 antigen.
by Joyce Karoline Silva, Lucas Neves de Farias, Tainã Lago, Luciana dos Santos Cardoso, Ricardo Khouri, Paulo Roberto Machado, Léa Cristina Castellucci
